Skip to main content
    C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.08
    -0.27 (-4.25%)

    Market Cap: $193.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cartesian Therapeutics Inc. (RNAC) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Cartesian Therapeutics are SAB Biotherapeutics (SABS), Cellectis SA (CLLS) and Sutro Biopharma (STRO). By market cap, Cartesian Therapeutics ranks 6th of the 13 companies on this page; Editas Medicine (EDIT) is the largest at $334.92M.

    Peer Comparison

    RNAC's ROIC of 147.2% is above the peer median of -42.3%, and its revenue growth of -92.9% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Cartesian Therapeutics (RNAC)$193.69MN/A179.8x0.0%147.2%-92.9%0.00%
    SAB Biotherapeutics Inc (SABS)$266.66MN/AN/A0.0%N/A-62.4%0.00%
    Cellectis SA (CLLS)$118.86MN/A1.8x0.0%-74.1%-85.4%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Sol Gel Technologies Ltd (SLGL)$180.46MN/A125.4x0.0%N/A-96.6%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Peer median$176.02MN/A5.0x0.0%-42.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Cartesian Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    SAB Biotherapeutics Inc (SABS)
    SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
    SABS competitors
    Cellectis SA (CLLS)
    Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors...
    CLLS competitors
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    Zentalis Pharmaceuticals Llc (ZNTL)
    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment...
    ZNTL competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors
    Sol Gel Technologies Ltd (SLGL)
    Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological...
    SLGL competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors

    Frequently Asked Questions About RNAC

    Who are Cartesian Therapeutics' main competitors?

    The companies most similar to Cartesian Therapeutics include SAB Biotherapeutics (SABS), Cellectis SA (CLLS), Sutro Biopharma (STRO), Zentalis Pharmaceuticals Llc (ZNTL) and Galectin Therapeutics (GALT), listed from the closest match.

    Who is Cartesian Therapeutics' biggest competitor?

    Editas Medicine (EDIT) is the largest of the similar companies at $334.92M; SAB Biotherapeutics (SABS) is the closest match by business profile, size, sector and industry.

    How does RNAC stock compare with its competitors?

    RNAC's P/S is 179.8x against a peer median of 5.0x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Cartesian Therapeutics' competitors pays a higher dividend?

    Cartesian Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Cartesian Therapeutics bigger than its competitors?

    No. Cartesian Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Editas Medicine (EDIT) at $334.92M.